Mechanism of Astragali Radix-Angelicae Sinensis Radix compatibility active ingredients in improving intimal hyperplasia based on network pharmacology / 中草药

ABSTRACT

Objective: To investigate the pharmacodynamics and possible targets of Astragali Radix (AR)-Angelicae Sinensis Radix (ASR) compatibility in improving intimal hyperplasia by using network pharmacology. Methods: The TCMSP database was used to obtain the active constituents of AR-ASR, and the Pharmmaper database was used to collect the targets corresponding to the active ingredients. Targets related to intimal hyperplasia were collected by Genecards, DigSeE, and OMIM databases, and compared with drug targets, common parts were screened as predictive targets for drug action. The use of STRING was to obtain the predicted relationship between target proteins, and to screen out the core targets according to the size of the relationship. Using the Cytoscape 3.6.1 software, a "drug-component-disease-target" network map and a core target interaction network map were drawn. KEGG pathway enrichment analysis and GO biological process analysis of core targets were performed using R language. Results: A total of 193 drug targets and 487 disease targets were obtained from the 20 active components of AR-ASR, mainly targeting EGFR, ESR1, ALB, MAPK8, PGR and other targets, involving PI3K-Akt, MAPK, Ras and other signaling pathways to play a role in anti-vascular intimal hyperplasia. Conclusion: Based on the network pharmacology, the possible targets and signaling pathways for the improvement of intimal hyperplasia by AR-ASR can be preliminarily explored, which may provide a reference for the study of the mechanism of the combination of AR and ASR.